Adaptive Biotechnologies Corp (NASDAQ: ADPT) saw its stock price surge 5.98% in after-hours trading on Thursday, following the release of its first-quarter 2025 financial results that surpassed analysts' expectations.

The biotechnology company reported a quarterly loss of $0.20 per share, significantly better than the analyst consensus estimate of a $0.31 loss. This represents a 35.48% beat on expectations and a 39.39% improvement from the $0.33 loss per share reported in the same quarter last year. Revenue for the quarter came in at $52.44 million, beating the analyst estimate of $42.7 million by 22.77% and showing a 25.14% increase from the $41.87 million reported in the prior-year period.

Adaptive Biotechnologies also provided a positive outlook for the full year, expecting revenue for its MRD (Minimal Residual Disease) business to be between $180 million and $190 million. The company anticipates full-year total operating expenses, including cost of revenue, to be between $335 million and $345 million, with a total company cash burn expected to be between $50 million and $60 million. These figures suggest that the company is managing its growth and expenses effectively, which likely contributed to investor optimism and the subsequent stock price increase.